Estrella Immunopharma, Inc.
ESLAW· Nasdaq
10-K due Mar 11 – Apr 2
No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 4 filings.
Up after 1 of 2, down after 1.
The stock’s move from the last close before each release to the first close after it, over the last 2 releases. Largest: −20.0% after Q2 2025.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Estrella Immunopharma, Inc. · CIK 1844417 · Engraved from SEC EDGAR
Based on 4 prior 10-K filings.
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.